Clinical Trial Search

Primary: Pharmacokinetics (PK) : Insulin Lispro Area Under the Concentration Curve Zero to Infinity (AUC[0-∞]) ) — 901; 1890; 3970; 1790 picomol per hour per L (pmol.h/L)

Primary: Rate of Conversion to Psychosis. — 4; 3 Participants — p=.51

Primary: Plasma Pharmacokinetics Parameters for Ganciclovir Area Under the Curve at 12 Hours (AUC12mgxh/L) — 47.2; 76.8 mgxh/L

Primary: Patients Requesting a Rapid HIV Test at a Community Pharmacy Study Site — 123 Participants

Primary: BD Nano™ PRO Pen Needle Compared to Terumo Nanopass® (Injection Pain) — 7.30 mm

Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -0.2; 13.6 percentage points — p=<0.0001

Primary: Reaction Time for Trials With High Abstraction Relative to Low Abstraction — 0.1247; 0.1444; 0.1022 seconds — p=0.031

Primary: Cumulative Incidence of Venous Thromboembolism (VTE) — 1.5; 2.2; 4.6 percentage of participants — p=<0.01

Primary: Peak Slip Speed — 2.8 meters/sec

Primary: Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8 — 176; 175 Participants

Primary: Lobene Stain Index of Stain Extent Scores 4 Weeks After Dentifrice Use — 1.35; 1.64 score on a scale

Primary: Early Clinical Response — 306; 303 Participants

Primary: Percent Change in Urine Protein From Baseline (Day 1) to Week 16 — -2.8; -51.2 percent change

Primary: Incidence of Treatment-Emergent Adverse Events — 29; 10; 1; 0 Participants

Primary: Duration of Study Recruitment — 6 months